Please find attached press release on the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended on March 31, 2026

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.3%1-day move

₹472.50

prior close

₹493.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9—

Up moveDown movePending

AI summary

Thyrocare Technologies reported strong Q4FY26 results with consolidated revenue of INR 223.95 crore, up 20% year-on-year, driven by 21% growth in the Pathology segment. Test volumes reached 59.0 million, marking a 29% YoY growth and reinforcing the company's volume leadership position. EBITDA grew 31% YoY to INR 75.09 crore, while PAT surged 128% YoY to INR 48.70 crore. For the full year FY26, revenue grew 21% to INR 829.04 crore, EBITDA increased 38% to INR 262.04 crore, and PAT rose 81% to INR 162.85 crore. The company expanded its test portfolio with advanced allergy testing and entered genomics with NIPT launch.

Likely market impact

Strong operational performance with robust revenue growth, margin expansion, and exceptional PAT growth signals effective cost management and operating leverage, which is positive for shareholders.